These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 7482575

  • 1. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
    Kontoghiorghes GJ.
    Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
    [Abstract] [Full Text] [Related]

  • 2. Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.
    Kontoghiorghes GJ.
    Arch Toxicol Suppl; 1996 Oct; 18():202-14. PubMed ID: 8678796
    [No Abstract] [Full Text] [Related]

  • 3. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
    Kontoghiorghes GJ.
    Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
    [Abstract] [Full Text] [Related]

  • 4. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A.
    Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
    [Abstract] [Full Text] [Related]

  • 5. Chelation of aluminium by combining DFO and L1 in rats.
    Blanusa M, Prester L, Varnai VM, Pavlović D, Kostial K, Jones MM, Singh PK.
    Toxicology; 2000 Jul 05; 147(3):151-6. PubMed ID: 10924797
    [Abstract] [Full Text] [Related]

  • 6. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A.
    Transfus Sci; 2000 Dec 05; 23(3):211-23. PubMed ID: 11099897
    [Abstract] [Full Text] [Related]

  • 7. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
    Kontoghiorghes GJ, Sheppard L, Hoffbrand AV, Charalambous J, Tikerpae J, Pippard MJ.
    J Clin Pathol; 1987 Apr 05; 40(4):404-8. PubMed ID: 3584483
    [Abstract] [Full Text] [Related]

  • 8. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).
    Fernández-Martín JL, Menéndez-Fraga P, Canteros MA, Díaz-López JB, Cannata-Andía JB.
    Clin Chim Acta; 1994 Oct 31; 230(2):137-45. PubMed ID: 7834865
    [Abstract] [Full Text] [Related]

  • 9. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
    Brock JH, Licéaga J, Arthur HM, Kontoghiorghes GJ.
    Am J Hematol; 1990 May 31; 34(1):21-5. PubMed ID: 2327400
    [Abstract] [Full Text] [Related]

  • 10. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
    Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L.
    Am J Hematol; 1993 Apr 31; 42(4):340-9. PubMed ID: 8493983
    [Abstract] [Full Text] [Related]

  • 11. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
    Morel I, Cillard J, Lescoat G, Sergent O, Pasdeloup N, Ocaktan AZ, Abdallah MA, Brissot P, Cillard P.
    Free Radic Biol Med; 1992 Nov 31; 13(5):499-508. PubMed ID: 1334028
    [Abstract] [Full Text] [Related]

  • 12. Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro.
    Cunningham JM, al-Refaie FN, Hunter AE, Sheppard LN, Hoffbrand AV.
    Eur J Haematol; 1994 Mar 31; 52(3):176-9. PubMed ID: 8168597
    [Abstract] [Full Text] [Related]

  • 13. Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity.
    Naves Díaz ML, Elorriaga R, Canteros A, Cannata Andía JB.
    Nephrol Dial Transplant; 1998 Mar 31; 13 Suppl 3():23-8. PubMed ID: 9568816
    [Abstract] [Full Text] [Related]

  • 14. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
    Sheppard LN, Kontoghiorghes GJ.
    Arzneimittelforschung; 1993 Jun 31; 43(6):659-63. PubMed ID: 8352819
    [Abstract] [Full Text] [Related]

  • 15. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Jun 31; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 16. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
    Chua AC, Ingram HA, Raymond KN, Baker E.
    Eur J Biochem; 2003 Apr 31; 270(8):1689-98. PubMed ID: 12694182
    [Abstract] [Full Text] [Related]

  • 17. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Barr J, Baillod RA.
    Arzneimittelforschung; 1994 Apr 31; 44(4):522-6. PubMed ID: 8011008
    [Abstract] [Full Text] [Related]

  • 18. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
    Srichairatanakool S, Thephinlap C, Phisalaphong C, Porter JB, Fucharoen S.
    Med Chem; 2007 Sep 31; 3(5):469-74. PubMed ID: 17897073
    [Abstract] [Full Text] [Related]

  • 19. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L.
    Br Med J (Clin Res Ed); 1987 Dec 12; 295(6612):1509-12. PubMed ID: 3122880
    [Abstract] [Full Text] [Related]

  • 20. The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.
    Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV, Dandona P.
    Biochem J; 1988 Aug 15; 254(1):239-44. PubMed ID: 3140797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.